Claims for Patent: 7,138,371

Summary for Patent: 7,138,371

Title:	Remodeling and glycoconjugation of peptides
Abstract:	The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.
Inventor(s):	DeFrees; Shawn (North Wales, PA), Zopf; David A. (Wayne, PA), Bowe; Caryn (Doylestown, PA)
Assignee:	Neose Technologies, Inc (Horsham, PA)
Application Number:	10/287,994
Patent Claims:	1. A covalent conjugate between a peptide and poly(ethylene glycol), wherein said poly(ethylene glycol) is covalently attached to said peptide at a glycosyl or amino acid residue of said peptide via an intact glycosyl linking group comprising a sialic acid residue covalently linked to said poly(ethylene glycol), wherein said sialic acid residue is covalently attached to said glycosyl or amino acid residue of said peptide by reaction between said peptide and a modified sugar donor comprising sialic acid covalently linked to said poly(ethylene glycol), and wherein said reaction is catalyzed by a sialyltransferase. 2. The covalent conjugate of claim 1, wherein said poly(ethylene glycol) and said sialic acid residue are covalently attached through a linker. 3. The covalent conjugate of claim 2, wherein said sialic acid residue has a structure according to the formula: ##STR00083## in which R is said poly(ethylene glycol) and said poly(ethylene glycol) is attached to said sialic acid residue through said linker. 4. The covalent conjugate of claim 1, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 5. The covalent conjugate of claim 3, wherein said sialic acid residue has a structure according to the formula: ##STR00084## in which n is an integer from 1 to 2000. 6. The covalent conjugate of claim 1, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse. 7. The covalent conjugate of claim 3 comprising a glycosyl moiety having a structure according to the formula: ##STR00085## in which G, G', G'' and G''' are members independently selected from moieties having the formula: ##STR00086## in which each a is a member independently selected from 0 and 1; each e is a member independently selected from the integers between 0 and 6; each j is a member independently selected from the integers between 0 and 100; and each v is a member independently selected from 0 and 1, with the proviso that at least one of G, G', G'' and G''' is a member selected from: --GlcNAc--Gal--Sia--R; and --GlcNAc--Sia--R wherein Sia--R has a structure according to the formula: ##STR00087## in which R is said poly(ethylene glycol) and said poly(ethylene glycol) is attached to said sialic acid through said linker. 8. The covalent conjugate of claim 7, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 9. The covalent conjugate of claim 7, wherein said sialic acid residue has a structure according to the formula: ##STR00088## in which n is an integer from 1 to 2000. 10. The covalent conjugate of claim 7, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse. 11. The covalent conjugate of claim 3 comprising a glycosyl moiety having a structure according to the formula: ##STR00089## in which a and b are members independently selected from 0 and 1; and Sia--R has a structure according to the formula: ##STR00090## wherein R is said poly(ethylene glycol). 12. The covalent conjugate of claim 11 wherein said sialic acid residue has a structure according to the formula: ##STR00091## 13. The covalent conjugate of claim 1 wherein said intact glycosyl linking group is covalently bound to a member selected from an amino acid residue of said peptide which is a member selected from Ser, Thr and Asn; a glycosyl residue covalently bound to an amino acid residue of said peptide which is a member selected from Ser, Thr and Asn; and combinations thereof. 14. The covalent conjugate of claim 1, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, Factor IX, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, Factor VIII, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, and human growth hormone. 15. A pharmaceutical formulation comprising said covalent conjugate according to claim 1 and a pharmaceutically acceptable carrier. 16. A method of treating or ameliorating a condition in a subject, said method comprising administering to said subject an amount of a covalent conjugate according to claim 1 effective to treat or ameliorate said condition; wherein the peptide in its unconjugated form is a therapeutic peptide. 17. A covalent conjugate between a peptide and poly(ethylene glycol), comprising a sialic acid residue having a structure according to the formula: ##STR00092## in which R is said poly(ethylene glycol) and said poly(ethylene glycol) attached to said sialic acid residue through a linker, and wherein said sialic acid residue is covalently attached to a glycosyl or amino acid residue of said peptide by reaction between said peptide and a modified sugar donor comprising said sialic acid residue covalently linked to said poly(ethylene glycol), and wherein said reaction is catalyzed by a sialyltransferase. 18. The covalent conjugate according to claim 17 wherein said sialic acid residue has a structure according to the formula: ##STR00093## in which n is an integer from 1 to 2000. 19. The covalent conjugate of claim 17, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, Factor IX, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, Factor VIII, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, and human growth hormone. 20. A pharmaceutical formulation comprising said covalent conjugate according to claim 17 and a pharmaceutically acceptable carrier. 21. A method of treating or ameliorating a condition in a subject, said method comprising administering to said subject an amount of a covalent conjugate according to claim 17 effective to treat or ameliorate said condition; wherein the peptide in its unconjugated form is a therapeutic peptide. 22. A covalent conjugate between a peptide and poly(ethylene glycol), comprising an intact glycosyl linking group having a structure according to the formula: ##STR00094## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are members independently selected from H, OH, a water-soluble polymer and linker-water-soluble polymer, with the proviso that at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 is a member selected from said water-soluble polymer and said linker-water-soluble polymer; R.sup.6 is a member selected from H, OH and polymers; X, Y, Z, A and B are members independently selected from O, NH, S, and CH.sub.2; and wherein said intact glycosyl linking group is covalently attached to a glycosyl or amino acid residue of said peptide by reaction between said peptide and a modified sugar donor comprising said intact glycosyl linking group covalently linked to said poly(ethylene glycol), and wherein said reaction is catalyzed by a glycosyltransferase. 23. The covalent conjugate according to claim 22 wherein a member selected from R.sup.3 and R.sup.4 is a member selected from poly(ethylene glycol) and linker-poly(ethylene glycol). 24. The covalent conjugate according to claim 22 wherein said intact glycosyl linking group has a structure according to the formula: ##STR00095## 25. The covalent conjugate of claim 22, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, Factor IX, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, Factor VIII, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, and human growth hormone. 26. A pharmaceutical formulation comprising said covalent conjugate according to claim 22 and a pharmaceutically acceptable carrier. 27. A method of treating or ameliorating a condition in a subject, said method comprising administering to said subject an amount of a covalent conjugate according to claim 22 effective to treat or ameliorate said condition; wherein the peptide in its unconjugated form is a therapeutic peptide. 28. A covalent conjugate of a G-CSF peptide and poly(ethylene glycol) comprising a sialic acid residue conjugated to said poly(ethylene glycol), wherein said residue has a structure according to the formula: ##STR00096## in which n is an integer from 1 to 2000; and wherein said sialic acid residue is covalently attached to a glycosyl or amino acid residue of said G-CSF peptide by reaction between said G-CSF peptide and a modified sugar donor comprising said sialic acid residue covalently linked to said poly(ethylene glycol), and wherein said reaction is catalyzed by a sialyltransferase. 29. A pharmaceutical formulation comprising said covalent conjugate according to claim 28 and a pharmaceutically acceptable carrier. 30. A method of stimulating granulocyte production in a subject, said method comprising administering to said subject a covalent conjugate according to claim 29 in an amount effective to stimulate said granulocyte production.

Details for Patent 7,138,371

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	January 16, 1978	7,138,371	2021-10-10
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	May 31, 2017	7,138,371	2021-10-10
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	August 11, 2022	7,138,371	2021-10-10